日本語English简体中文 繁體中文

4880 CellSource Co.,Ltd.セルソースTSE Standard / Pharmaceuticals

0 posts

CellSource Co.,Ltd. (4880) at a glance

Code
4880
Company
CellSource Co.,Ltd.
Local name
セルソース
Market
TSE Standard
Sector
Pharmaceuticals
Share price
¥262 -8.0 (-2.96%) Nov 20 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

CellSource Co.,Ltd. (4880) Stock Price HistoryNear an all-time low

CellSource Co.,Ltd. closed at ¥262 on Nov 20, 2026, −16.0% over 1 month, −48.3% over 1 year.

¥317¥262Oct 20Nov 20
Price5-day MA25-day MANikkei 225
1-Month High¥317Oct 21
1-Month Low¥262Nov 20
1-Week Change−7.1%vs Nov 13
1-Month Change−16.0%vs Oct 20

If you had invested ¥100,000 1 month ago, it would be worth ¥83,974 today (−16.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −11.9%, while this stock moved −16.0%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥262−8−2.96%
Nov 18 (Wed)¥270−2−0.74%
Nov 17 (Tue)¥272−6−2.16%
Nov 16 (Mon)¥278−4−1.42%
Nov 13 (Fri)¥282+1+0.36%
Nov 12 (Thu)¥281+0+0.00%
Nov 11 (Wed)¥281−5−1.75%
Nov 10 (Tue)¥286+5+1.78%
Nov 9 (Mon)¥281+10+3.69%
Nov 6 (Fri)¥271−19−6.55%
2026-09-08 2026年10月期第3四半期決算短信〔日本基準〕(非連結) / 業績予想の修正に関するお知らせ / 本店移転及び特別損失の計上(見込み)に関するお知らせ2026-09-09 主要株主である筆頭株主及び主要株主並びにその他の関係会社の異動(予定)並びに公…2026-10-13 棚卸資産評価損及び特別損失の計上(見込み)に関するお知らせ¥359¥262Aug 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
3-Month High¥359Sep 1
3-Month Low¥262Nov 20
1-Month Change−16.0%vs Oct 20
3-Month Change−25.4%vs Aug 20

If you had invested ¥100,000 3 months ago, it would be worth ¥74,644 today (−25.4%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −14.8%, while this stock moved −25.4%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥262−8−2.96%
Nov 18 (Wed)¥270−2−0.74%
Nov 17 (Tue)¥272−6−2.16%
Nov 16 (Mon)¥278−4−1.42%
Nov 13 (Fri)¥282+1+0.36%
Nov 12 (Thu)¥281+0+0.00%
Nov 11 (Wed)¥281−5−1.75%
Nov 10 (Tue)¥286+5+1.78%
Nov 9 (Mon)¥281+10+3.69%
Nov 6 (Fri)¥271−19−6.55%
2026-09-08 2026年10月期第3四半期決算短信〔日本基準〕(非連結) / 業績予想の修正に関するお知らせ / 本店移転及び特別損失の計上(見込み)に関するお知らせ2026-09-09 主要株主である筆頭株主及び主要株主並びにその他の関係会社の異動(予定)並びに公…2026-10-13 棚卸資産評価損及び特別損失の計上(見込み)に関するお知らせ¥367¥262May 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
6-Month High¥367May 22
6-Month Low¥262Nov 20
3-Month Change−25.4%vs Aug 20
6-Month Change−24.5%vs May 20

If you had invested ¥100,000 6 months ago, it would be worth ¥75,504 today (−24.5%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −5.6%, while this stock moved −24.5%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥262−8.4%
Oct 2026¥286−8.3%
Sep 2026¥312−12.6%
Aug 2026¥357+10.9%
Jul 2026¥322+3.2%
Jun 2026¥312−10.3%
May 2026¥348−5.2%
2026-09-08 2026年10月期第3四半期決算短信〔日本基準〕(非連結) / 業績予想の修正に関するお知らせ / 本店移転及び特別損失の計上(見込み)に関するお知らせ2026-09-09 主要株主である筆頭株主及び主要株主並びにその他の関係会社の異動(予定)並びに公…2026-10-13 棚卸資産評価損及び特別損失の計上(見込み)に関するお知らせ¥517¥262Nov 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
52-Week High¥517Nov 28
52-Week Low¥262Nov 20
Year to Date−34.3%vs Dec 30
From 52-Week High−49.3%Nov 28

If you had invested ¥100,000 1 year ago, it would be worth ¥51,677 today (−48.3%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +13.3%, while this stock moved −48.3%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥262−8.4%
Oct 2026¥286−8.3%
Sep 2026¥312−12.6%
Aug 2026¥357+10.9%
Jul 2026¥322+3.2%
Jun 2026¥312−10.3%
May 2026¥348−5.2%
Apr 2026¥367−1.3%
Mar 2026¥372−12.1%
Feb 2026¥423+5.0%
Jan 2026¥403+1.0%
Dec 2025¥399−22.8%
Nov 2025¥517―
¥1,664¥262Nov 20, 2023Nov 20, 2026
Price13-week MA26-week MANikkei 225
3-Year High¥1,664Dec 11, 2023
3-Year Low¥262Nov 20, 2026
Annualized Return−45.6%
Max Drawdown−84.3%

If you had invested ¥100,000 3 years ago, it would be worth ¥16,123 today (−83.9%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +67.8%, while this stock moved −83.9%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥262−34.3%
2025¥399―
¥7,530¥262Nov 22, 2021Nov 20, 2026
Price13-week MA26-week MANikkei 225
5-Year High¥7,530Dec 6, 2021
5-Year Low¥262Nov 20, 2026
Annualized Return−48.0%
Max Drawdown−96.5%

If you had invested ¥100,000 5 years ago, it would be worth ¥3,819 today (−96.2%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +96.3%, while this stock moved −96.2%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥262−34.3%
2025¥399―
¥7,550¥262Oct 28, 2019Nov 20, 2026
Price1-year MA2-year MANikkei 225
All-Time High¥7,550Nov 2021
All-Time Low¥262Nov 2026
Total Change−73.2%vs Oct 2019
Annualized Return−17.0%

If you had invested ¥100,000 in Oct 2019, it would be worth ¥26,826 today (−73.2%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +138.6%, while this stock moved −73.2%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥262−34.3%
2025¥399−52.0%
2024¥832−34.9%
2023¥1,279−68.1%
2022¥4,005−26.2%
2021¥5,430+50.0%
2020¥3,620+188.3%
2019¥1,256―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Oct 2019). Please check the latest prices before trading.

CellSource Co.,Ltd. (4880) financial indicators

PBR
0.87
ROE
-2.09%
Dividend yield
0.00%

See all financial indicators for CellSource Co.,Ltd. (market cap, DOE, equity ratio, EV, EBITDA, ROIC and more)

PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.

Key features of CellSource Co.,Ltd. (4880)

Business overview

The company was founded in November 2015 to industrialize regenerative medicine. For medical institutions that provide regenerative medicine, it offers contract processing and storage of tissues and cells derived from blood and fat, support services for regulatory compliance and management under Japan's regenerative medicine laws, medical device sales and cosmetics sales. In its blood-derived processing service, it makes platelet-rich plasma (PRP) from blood that medical institutions collect from patients, then concentrates growth factors and freeze-dries it into PFC-FD. Medical institutions use this in self-paid treatments, mainly for knee osteoarthritis and infertility.

Summarized from the annual securities report (fiscal year ended October 2025) filed on EDINET.

Position within Pharmaceuticals (79 companies)

PBR0.87xBelow the sector median of 1.86x (No. 17 from the lowest)
ROE-2.09%No. 36 in the sector (highest first); median 4.17%
Market cap¥5.2 bnNo. 63 in the sector (largest first)

Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.

Price milestones

52-week high¥5172025/11/28
52-week low¥26211/20
Current position0.0%Where the low is 0% and the high is 100% (close on 11/20: ¥262)
Year to date-34.3%No. 57 of 77 in the sector (best first)
1 year-48.3%

Based on closing prices (adjusted for stock splits, excluding dividends).

Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.

Recent disclosures (TDnet, in Japanese)

Filings from the past 12 months (8).

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No posts yet. Be the first to write something.

Write on the CellSource Co.,Ltd. board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Japanese stocks in English

Japanese Stock Message Board: stocks available in English

Other boards in English